Nucleic acid stabilizing solution for vaccines, therapy, diagnostics, storage, and transport
US12263217B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 3, 2021 |
| Grant date | Apr 1, 2025 |
| Priority date | — |
| Expiry date | Jan 13, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55511
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chemical compositions and/or mixtures that allow nucleic acid to remain stable at ambient temperatures. The disclosed technology includes a solution and manufacturing methods thereof. The solution includes a chelating agent, a buffering agent, and a salt. The solution is configured to protect RNA and/or an RNA-based vaccine added to the solution and prevents or reduces degradation of the RNA and/or the RNA-based vaccine for a duration of 2 to 180 days over a temperature range of −20 degrees C. to +38 degrees C. The chelating agent can comprise ethylenediaminetetraacetic acid (EDTA). The buffering agent can comprise tris(hydroxymethyl)aminomethane (TRIS). The salt can comprise NaCl. The solution is configured to preserve an injectable mRNA vaccine added to the solution, and the solution is safe for injection into mammals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.